Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma

Neoplasia (United States)

Volumn 14, Issue 6, 2012, Pages 535-546

  Boysen, Gunther ^a,d   Bausch Fluck, Damaris ^b   Thoma, Claudio R ^b   Nowicka, Anna M ^a   Stiehl, Daniel P ^c   Cima, Igor ^b   Luu, Van Duc ^a   von Teichman, Adriana ^a   Hermanns, Thomas ^a   Sulser, Tullio ^a   Ingold Heppner, Barbara ^a,e   Fankhauser, Niklaus ^b   Wenger, Roland H ^c   Krek, Wilhelm ^b   Schraml, Peter ^a   Wollscheid, Bernd ^b   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ADAM10 ENDOPEPTIDASE; ARYLDIALKYLPHOSPHATASE 1; CADMIUM 109; CD146 ANTIGEN; CD40 ANTIGEN; CD47 ANTIGEN; CD63 ANTIGEN; CD70 ANTIGEN; CD82 ANTIGEN; CD97 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DECAPENTAPLEGIC PROTEIN; ENDOTHELIAL PROTEIN C RECEPTOR; EPHRIN RECEPTOR A2; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLYCOPROTEIN; HERMES ANTIGEN; HLA B ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERCELLULAR ADHESION MOLECULE 1; MULTIDRUG RESISTANCE PROTEIN 1; NECTIN 1; NERVE CELL ADHESION MOLECULE; THIORPHAN; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL INVASION; CHROMATIN IMMUNOPRECIPITATION; COMPUTER MODEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KIDNEY CARCINOMA; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 84865652325     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1596/neo.12130     Document Type: Article

References (47)

1. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, Yeung SC, and Lee MH (2009). Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28, 2581-2592.
2. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, and Broder GJ (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14, 831-838.
3. Teicher BA, Lazo JS, and Sartorelli AC (1981). Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41, 73-81.
4. Toffoli S and Michiels C (2008). Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J 275, 2991-3002.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356, 115-124.
6. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, and Wilding G (2007). Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178, 1883-1887.
7. Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, et al. (2007). Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13, 1801-1809.
8. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, et al. (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524.
9. Hood BL, Malehorn DE, Conrads TP, and Bigbee WL (2009). Serum proteomics using mass spectrometry. Methods Mol Biol 520, 107-128.
10. Wollscheid B, Bausch-Fluck D, Henderson C, O'Brien R, Bibel M, Schiess R, Aebersold R, and Watts JD (2009). Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol 27, 378-386.
11. Schiess R, Wollscheid B, and Aebersold R (2009). Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 3, 33-44.
12. Luu VD, Fischer B, von Teichman A, Boysen G, Mertz K, Zimmermann P, Moch H, and Schraml P (2008). Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma [in German]. Pathologe 29(suppl 2), 303-307.
13. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, et al. (2006). Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66, 2000-2011.
14. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJ, Schalken JA, van den Brandt PA, and Oosterwijk E (2005). Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 5, 57.
15. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al. (1994). Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91, 9700-9704.
16. Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, and Moch H (2011). VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Cancer Res 71, 5500-5511.
17. Iliopoulos O, Ohh M, and Kaelin WG Jr (1998). pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 95, 11661-11666.
18. Schraml P, Hergovich A, Hatz F, Amin MB, Lim SD, Krek W, Mihatsch MJ, and Moch H (2003). Relevance of nuclear and cytoplasmic von Hippel-Lindau protein expression for renal carcinoma progression. Am J Pathol 163, 1013-1020.
19. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, and Krek W (2003). Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5, 64-70.
20. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, and Krek W (1999). The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitinprotein ligase activity. Genes Dev 13, 1822-1833.
21. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
22. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, and Pavletich NP (2002). Structure of an HIF-1α -pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886-1889.
23. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG Jr (2001). HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468.
24. Kaelin WG Jr (2007). The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13, 680s-684s.
25. Hergovich A, Lisztwan J, Thoma CR, Wirbelauer C, Barry RE, and Krek W (2006). Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol Cell Biol 26, 5784-5796.
26. Thoma CR, Frew IJ, Hoerner CR, Montani M, Moch H, and Krek W (2007). pVHL and GSK3β are components of a primary cilium-maintenance signalling network. Nat Cell Biol 9, 588-595.
27. Li XJ, Zhang H, Ranish JA, and Aebersold R (2003). Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry. Anal Chem 75, 6648-6657.
28. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi OP (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4, 844-847.
29. Dahinden C, Ingold B, Wild P, Boysen G, Luu VD, Montani M, Kristiansen G, Sulser T, Buhlmann P, Moch H, et al. (2010). Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 16, 88-98.
30. Metzen E, Stiehl DP, Doege K, Marxsen JH, Hellwig-Burgel T, and Jelkmann W (2005). Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 387, 711-717.
31. Suzuki R and Shimodaira H (2006). Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22, 1540-1542.
32. Team RDC (2008). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
33. Liaw A and Wiener M (2002). Classification and regression by random forest. R News 2, 18-22.
34. Ishimaru F and Shipp MA (1995). Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements. Blood 85, 3199-3207.
35. Haouas H, Morello D, Lavenu A, Billard M, Jasmin C, and Boucheix C (1995). Characterization of the 5′ region of the CD10/neutral endopeptidase 24.11 gene. Biochem Biophys Res Commun 207, 933-942.
36. Sezaki N, Ishimaru F, Tabayashi T, Kataoka I, Nakase K, Fujii K, Kozuka T, Nakayama H, Harada M, and Tanimoto M (2003). The type 1 CD10/neutral endopeptidase 24.11 promoter: functional characterization of the 5′-untranslated region. Br J Haematol 123, 177-183.
37. Wenger RH, Stiehl DP, and Camenisch G (2005). Integration of oxygen signaling at the consensus HRE. Sci STKE 2005, re12.
38. Langner C, Ratschek M, Rehak P, Schips L, and Zigeuner R (2004). CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology 45, 460-467.
39. Chu P and Arber DA (2000). Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 113, 374-382.
40. Butnor KJ, Nicholson AG, Allred DC, Zander DS, Henderson DW, Barrios R, Haque AK, Allen TC, Killen DE, and Cagle PT (2006). Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 130, 823-827.
41. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, et al. (2008). HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435-446.
42. Avery AK, Beckstead J, Renshaw AA, and Corless CL (2000). Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 24, 203-210.
43. Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, and Maitra A (2009). The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8, 618-626.
44. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, et al. (2007). Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67, 3878-3887.
45. Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener PA, Moch H, and Rubin MA (2007). Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 38, 1454-1462.
46. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, Sauter G, Mihatsch MJ, and Moch H (2002). VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196, 186-193.
47. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, and Dahlback B (2009). Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15, 4742-4749.